Guido Würth

Seminars

Tuesday 21st July 2026
Roundtable Discussion – Designing Effective TRP Targets by Exploring Emerging Clinical Candidates & Lessons from Other Targeted Therapies
10:00 am

Join your colleagues for a deep-dive discussion in smaller groups to map out the next generation of TRP targets. You will brainstorm high-potential clinical candidates and cross-pollinate ideas from the ADC space to sharpen selection strategy before sharing your table’s thoughts and discussion back to the group.

  • Identifying optimal tumor targets by evaluating density, internalization, and off-target risk
  • Exploring current targets under development and their potential clinical impact
  • Applying lessons from antibody-drug conjugates and other targeted therapies to guide RLT target selection
Tuesday 21st July 2026
Fireside Chat: What I Wish I Knew When Entering Radiopharma
2:30 pm

Thinking about entering radiopharma – or wish you’d known more before you did? Join seasoned leaders from R&D, CMC, clinical, and commercial as they share hard-won lessons, practical pitfalls, and insider insights across the entire development journey, and bring your questions to those who’ve navigated it firsthand.

  • R&D and Preclinical: novel target choices, targeting molecules, linkers, chelators, preclinical dosimetry and more
  • CMC and Regulatory: isotope properties, differences in supply chain, logistics networks, CMC innovations, regulatory considerations and more
  • Clinical Development: clinical trial design, working with sites, working with clinical stakeholders, patient centric approaches and more
Thursday 23rd July 2026
Engineering the Therapeutic Window in HER2 Radioligand Therapy: First-in-Human Experience with Affibody molecule ABY-271
12:00 pm
  • Clinical translation underway: First-in-human Phase 1 study of HER2-targeted radioligand moving forward with dose escalation
  • Expanding the therapeutic window: Protein mass-dose optimization to address HER2-low disease
  • Broadening the radiopharma space: Addressing physiological HER2 expression to unlock new RLT opportunities